Publication date: Oct 01, 2026
Accelerated intermittent theta burst stimulation (aiTBS) is a time-efficient treatment for treatment-resistant depression (TRD), but highly intensive protocols like SNT are difficult to implement due to MRI-guided targeting and high session frequency. This study evaluated the feasibility and clinical outcomes of a five-day, intermediate-session frequency aiTBS protocol delivered without neuronavigation and characterized response heterogeneity using group-based trajectory modelling. This retrospective analysis included 48 adult patients with TRD who received 7 sessions per day of aiTBS for 5 days (35 sessions) targeting the left dorsolateral prefrontal cortex using the modified Beam F3 approach without neuronavigation as part of clinical care. The primary outcome was change in the Patient Health Questionnaire-9 (PHQ-9) score at Day 5 as assessed with a linear mixed-effects model with Holm-Bonferroni correction. Most patients completed the five-day treatment course (89. 6%), and symptom data were available for 91% at Day 5. The Day-5 response rate (≥50% PHQ-9 reduction) was 16. 7%. PHQ-9 scores decreased significantly from baseline at Day 5 (LSMD = -2. 97), with further reductions at two weeks (LSMD = -6. 81) and stability at one month (LSMD = -6. 50), although follow-up data were incomplete. Trajectory modelling identified four distinct symptom patterns, underscoring variability in response. This intermediate-session frequency aiTBS protocol was feasible to implement in a real-world clinical setting. While modest symptom reduction was observed, substantial missing data after Day 5 limit confidence in longer-term outcomes. Individual trajectories varied, highlighting the need for personalized approaches and improved follow-up strategies.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | included |
| drug | DRUGBANK | Tricyclazole |
| disease | MESH | Depressive Disorder Treatment-Resistant |